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In the early part of this century, Otto Warburg postulated that
tumours were acidic because the rate at which they produced lactic
acid was ‘remarkable’ (Warburg, 1956). Subsequent measurement
of pH in a variety of solid tumours with microelectrodes appar-
ently confirmed this hypothesis (Wike-Hooley et al, 1984). It is
assumed that microelectrode measurements primarily interrogate
extracellular (interstitial) volumes. However, in-vivo 31P magnetic
resonance spectroscopy (MRS) of endogenous intracellular
inorganic phosphate (Pi) measures an intracellular pH (pHi) which
is neutral-to-alkaline in the same or similar tumours (Griffiths,
1991; Negendank, 1992). Thus, the apparent acidity of the extra-
cellular (interstitial) pH (pHe) does not translate to an acidic pHi.
Recently, 31P MRS methods have been developed to simultane-
ously measure the pHi and pHe of tumours using endogenous Pi
and exogenous 3-aminopropylphosphonate (3-APP), respectively
(Gillies et al, 1994). This method has clearly shown, in a number
of solid tumour xenografts, that the pHi of tumour cells is
neutral–alkaline, while the pHe of the same tumours is acidic
(McCoy et al, 1995; Raghunand et al, 1999a). Thus, solid tumours
generally have substantial acid-outside pH gradients.
Acid-outside pH gradients have a number of important
sequellae that are germane to cancer, including a theoretically
reduced partitioning of weakly basic chemotherapeutic drugs into
the relatively alkaline cells. This phenomenon has its basis in the
‘ion-trapping’ hypothesis wherein weak bases partition into, and
are sequestered by, acidic compartments, such as the extracellular
fluid (Roos, 1978). This occurs because uncharged, organic free
bases are much more permeable than their protonated and charged
counterparts and establish equal concentrations on both sides of
the membrane (Gillies and Deamer, 1978). Since the ratio of
charged–uncharged species increases with lower pH, more total
base is found in acidic compartments. This hypothesis is applic-
able to weakly basic chemotherapeutic drugs, such as doxorubicin
(pKa = 7.6), which is one of the most widely prescribed anti-
neoplastic agents used in the treatment of breast cancer (Taylor et
al, 1991).
MATERIALS AND METHODS
Cell and tumour growth
MCF-7 cells were obtained from W S Dalton (Arizona Cancer
Center) and cultured in RPMI-1640/DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% fetal bovine serum
(FBS) (HyClone, Logan, UT, USA). For in vivo culturing, a
suspension of 5 ´106 MCF-7 cells in 0.05ml of Hank’s balanced
salt solution were implanted in the mammary fat pads of 6- to 7-
week-old female severe combined immunodeficient (SCID) mice.
Since MCF-7 cells are oestrogen-dependent, 17b-oestradiol
pellets (0.72mg, 60-day release; Innovative Research of America,
Sarasota, FL, USA) were subcutaneously implanted in the
shoulder region of the mice by means of a 12-gauge trochar
(Innovative Research) 2 days prior to tumour inoculation.
Magnetic resonance spectroscopy
Prior to MRS, mice were anaesthetized with a combination of
ketamine (72mgkg–1), xylazine (6mg kg–1) and acepromazine
(6mg kg–1). A 3/4¢¢, 24-gauge catheter (Elf Sanofi Inc., Overland
Park, KS, USA), connected to a 1.58mm intradermal (i.d.)
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enough to extend out of the magnet was inserted into the intraperi-
toneal (i.p.) cavity of the anaesthetized animal. The mouse was
then immobilized on a home-built probe with a coil tunable to
1H or 31P. After shimming the magnet, 3-APP (0.15–0.3 ml,
128 mg ml–1, pH 7.4) was injected into the mouse via the i.p.
catheter. Volume-selective 31P spectra were acquired at 4.7 T on a
Bruker Biospec with the ISIS sequence (Ordidge et al, 1988) with
adiabatic slice-selective and excitation pulses repeated every
10–12 s, using a gradient strength of 75 mT m–1. In all cases, a
dwell time of 62.5 ms was employed, and 8192 data points were
collected from 184 transients. Scout images of the tumour and
surrounding abdominal tissue were obtained each time in order to
guide the positioning of the voxel. The large spectral widths
employed resulted in up to a 1 mm difference in the positioning of
the voxel containing either a-NTP or 3-APP, and the voxel
containing the central frequency. This chemical shift artefact was
not corrected for, but voxel sizes and placement were chosen so as
to minimize the contribution of signal arising from the mouse
body wall, while covering as much of the tumour as possible.
Measurement of intracellular pH in vitro
Intracellular pH (pHi) was measured in vitro using the fluorescent
dye, SNARF-1, as described previously (Martinez-Zaguilan et al,
1991). Briefly, MCF-7 cells were grown onto 9 ´ 22 mm glass
coverslips, washed three times with buffer A (1.3 mM calcium
chloride, 1 mM magnesium sulphate, 5.4 mM potassium chloride,
0.44 mM KH2PO4, 110 mM sodium chloride, 0.35 mM NaH2PO4,
5m M glucose, 2 mM glutamine and 5 mM HEPES, 5 mM MES,
10 mM sodium hydrogen carbonate (NaHCO3) at a pH of 7.15 at
37°C and subsequently incubated for 30 min at 37°C, in a 5%
carbon dioxide atmosphere with 3 ml of buffer A containing
10 mM acetoxymethylester SNARF-1 (Molecular Probes, Eugene,
OR, USA). This was followed by a second incubation in buffer A
for 45 min to allow for complete hydrolysis of the dye. Coverslips
were then placed in a holder/perfusion device and inserted into a
fluorometer cuvette and fluorescence measurements were acquired
at an excitation of 534 nm with the emission sequentially sampled
at 584 and 644 nm in an SLM8000C (SLM, Urbana, IL, USA).
The ratio (R) of fluorescence intensities of emissions at
584 and 644 nm was converted to pHi values using the equation:
pH = 7.38 + log10 0.822 + log10 [(R – 0.458)/(1.928 – R)]. Data
are presented as mean ± s.e.m. of six independent measurements.
Doxorubicin uptake and cytotoxicity in vitro
MCF-7 cells were grown to confluence in 6-well plates at which
time the cells were incubated in DMEM/F12 containing 20 mM
HEPES, 20 mM MES, 10% FBS and 0.208 mCi per well of 14C
doxorubicin (Amersham) for 30 min at 37°C in a 5% carbon
dioxide atmosphere at pH of 6.8 and 7.4 respectively. After the
incubation, the plates were placed on ice and washed five times
with ice-cold HBSS, followed by extraction with 1.0 ml of 0.1 N
NaOH for 1 h at 4°C. Samples were divided into equal aliquots for
determination of protein content using the Bradford assay (Bio-
Rad), and radioactivity using liquid scintillation counting.
Cytotoxicity was determined as previously described (Gillies et
al, 1986). Briefly, cells were grown to log phase in 96-well plates
and medium was exchanged for one at either pH 6.8 or 7.4
containing the indicated concentrations of doxorubicin. Medium
pH was buffered using non-volatile buffers (10 mM MES, 20 mM
HEPES and 10 mM TRICINE) in combination with bicarbonate
concentrations that were adjusted to be in equilibrium with 5%
ambient carbon dioxide. Twenty-four hours later, regular growth
medium was replaced and cells allowed to grow a subsequent 72 h,
after which time they were fixed and stained with crystal violet for
determination of cell number.
Calculation of theoretical drug distributions
Cytoplasmic–extracellular drug ratios were calculated at the
steady-state using methods described previously (Roos, 1978;
Raghunand et al, 1999b). Briefly, the ratio of protonated (charged)
to deprotonated (uncharged) doxorubicin were calculated from the
Henderson–Hasselbach equation in both intracellular and extra-
cellular compartments using the pHi and pHe, respectively, and a
drug pKa of 7.6. The concentration of the uncharged specie was
set to 1.0 on both sides of the membrane and the total concentra-
tion was calculated as the sum of (charged + uncharged). Data
were expressed as a ratio of intra- to extracellular concentrations.
Enhancement was calculated as the ratio at high pH, relative to
that at low pH.
Tumour growth statistics
Tumour size was measured with calipers and calculated as:
[(width)2 ´ length]/2. Data were linearized by converting volumes
(in mm3) to their cube roots. The least squares regression line of
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Table 1 Theoretical and measured enhancement of doxorubicin uptake
caused by increasing extracellular pH in vitro and in vivo
In vitro Low pHe High pHe
Extracellular pH 6.8 7.4
Intracellular pH (n) 7.05 ± 0.06 (22) 7.20 ± 0.07 (5)
Theoretical ratio 0.69 ± 0.07 1.36 ± 0.17
Theoretical enhancement 1.97 ± 0.45
Doxorubicin uptake (n) 65.1 ± 2.7 (6) 166.9 ± 9.1 (6)
Uptake enhancement 2.56 ± 0.25
EC50 (mM) 0.27 0.12
Toxicity enhancement 2.25
In vivo Control + NaHCO3
pHe (800 mm3 tumour) 6.99 ± 0.11 7.84 ± 0.13
pHi (800 mm3 tumour) 7.15 ± 0.08 7.39 ± 0.13
pH gradient +0.16 –0.45
Theoretical ratio 0.6 1.6
Theoretical enhancement 2.5
Table 2 Tumour growth statistics
AB C D
No. mice 17 13 12 13
T–C (d to 300 mm3)– – 1 5 2 2
T/C (%) – – 0.47 0.29
Growth rate (d–1) 0.206 0.215 0.156 0.092
Standard deviation 0.094 0.060 0.067 0.047
P vs group A – 0.732 0.031 0.002
P vs group B 0.732 – 0.027 0.001
P vs group C 0.031 0.027 – 0.008
P vs group D 0.002 0.001 0.008 –the cube root volumes from day 9 onward were fit for each mouse
with non-zero tumour growth. Three-way analyses of variance
were used to examine the effect of different experiments, injection
(doxorubicin vs saline), and water (plain vs bicarbonate). The
differences between experiments were not significant (P= 0.767)
and, hence, data from all experiments were pooled for further two-
way analyses of variance. Tumour cell log kill was calculated from
the equation [(T–C)/3.32Td], where T and C are the number of
days it took for treated and control groups, respectively, to reach
1000mm3. Td is the exponential doubling time of the treated group
(Corbett et al, 1982). T/C was calculated as the ratio of the median
volumes of treated and control groups on day 20. T/C < 44% is
considered significant by the Division of Cancer Treatment
(National Cancer Institute), while a T/C value of < 10% (DN-2
level activity) is considered highly significant.
RESULTS
pH affects doxorubicin distribution and cytotoxicity in
vitro
Solid tumours generally exhibit pHe values of 6.7–6.8 (Wike-
Hooley et al, 1984; Griffiths, 1991; Gillies et al, 1994; McCoy
et al, 1995; Raghunand et al, 1999a). In vitro, MCF-7 cells at
medium pH values of 6.8 and 7.4 have pHi values of 7.05 ±0.06
and 7.20 ±0.07, respectively, as measured with fluorescence
(Figure 1A). Thus, according to theory (see Methods), the pH
gradient of +0.25 at pHe = 6.8 will yield an intracellular–extracel-
lular doxorubicin ratio of 0.69 ±0.07, whereas at pHe = 7.4,
the ratio will be 1.36 ±0.17 (Table 1). Hence, there will be a
1.97 ±0.45-fold enhancement of the steady-state intracellular drug
concentration as pHe is raised from 6.8 to 7.4. The empirical
steady-state levels of 14C doxorubicin in MCF-7 cells at medium
pH values of 6.8 and 7.4 show a 2.56 ±0.25-fold enhancement
(Figure 1B), which is in good agreement with theory.
The difference in intracellular levels of doxorubicin between
low and high pHe values should give rise to differences in cyto-
toxicity. Figure 1C shows that, following a 24-h treatment, the EC50
of doxorubicin in MCF-7 cells is 0.27mm at pH 6.8, compared to
0.12mm at pH 7.4. One-hour treatments with doxorubicin yielded
essentially the same results, although both EC50 values were higher.
Similar data for doxorubicin have been reported elsewhere
(Tannock and Rotin, 1989; Simon and Schindler, 1994). In the
current study, the 2.25-fold enhancement of doxorubicin cyto-
toxicity at pH 7.4 compared to pH 6.8 is similar in magnitude to
both theory and the empirical doxorubicin distribution ratio (cf.
Table 1). Thus, the enhanced cytotoxicity at high pHe is likely due
to increased partitioning of doxorubicin into cells.
Bicarbonate raises pHe in vivo
While there is substantial evidence that doxorubicin is more effec-
tive at higher pHe, this phenomenon is of limited utility unless the
pHe of tumours can be manipulated in vivo. For the current exper-
iments, pHe was raised via sodium bicarbonate-induced metabolic
alkalosis. However, the addition of bicarbonate could have impor-
tant negative sequelae, since it is osmotically active and could
cause hypernatraemia. To determine the maximum tolerated doses
of bicarbonate, eight different cohorts of SCID mice were given
NaHCO3-supplemented water to drink ad libitum. Bicarbonate
concentrations ranged from 0 to 250mM. Animal weights and
water consumption were monitored daily. For bicarbonate concen-
trations up to 225mM, weight gain and subjective parameters (e.g.
grooming behaviour and activity) were unaffected compared to
water controls for up to 9 weeks (data not shown). In a separate
experiment, animals were given 200mMNaHCO3 ad lib. Four to
10 days following commencement of bicarbonate therapy, pHi and
pHe were measured using 31P MRS. A representative 31P spectrum
from an untreated MCF-7 cell tumour is shown in Figure 2A. In
this Figure, the pHe measured by 3-APP is 6.57 and the pHi
measured by Pi is 6.95. Figure 2B shows the region containing the
3-APP resonance from a representative 31P MRS spectrum of
pH and chemotherapy1007
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Figure 1In vitro effects of pH on doxorubicin chemotherapy. (A)
Intracellular pH of MCF-7 cells in-vitro. MCF-7 cells grown on coverslips were
loaded with SNARF-1 fluorescent dye and the intracellular pH was measured
as described in Methods. (B) Doxorubicin levels in MCF-7 cells as a function
of pHe. MCF-7 cells were incubated with 14C doxorubicin for 30min at
medium pH of 6.8 or 7.4, after which time cells were washed and
radioactivity determined (see Methods). Data are expressed as pmol mg
protein–1. (C) Cytotoxicity of doxorubicin as a function of pHe. MCF-7 cells
were grown in 96-well plates to sub-confluence, at which time they were
treated with doxorubicin at the indicated concentrations. Ninety-six hours
later, media were removed and remaining cell numbers were determined by
crystal violet staining, as described previously (Gillies et al, 1986). Data are
shown for MCF-7 cells at pH 6.8 and 7.4. OD, optical densityMCF-7 tumours obtained 4 days following substitution of drinking
water with 200 mM NaHCO3. Note the shift in the position of the
3-APP resonance relative to controls indicating a significant
alkalinization of pHe. All other resonances (Pi, PME, ATP) were
statistically indistinguishable from the controls. In this example,
the measured pHe was 7.72. Thus, NaHCO3 can significantly
increase pHe.
Results from all of the MRS-based pH measurements are shown
in Figure 3A, expressed as a function of tumour size. Note that in
untreated MCF-7 tumours (triangles), the pHe (open) and pHi
(closed) decrease with approximately the same slope with
increasing tumour size. Thus, the pH gradient is relatively constant
at 0.22 ± 0.09 pH unit, consistent with previous reports
(Raghunand et al, 1999a). In animals supplemented with HCO3
–,
the measured pHe values (open circles) are significantly higher
than the measured pHi values (closed circles). This is significantly
different than the pHe and pHi of control animals. The direction of
the plasmalemmal (in–out) pH gradient is shown by arrows in the
Figure and it is clear that the direction is reversed in all NaHCO3-
treated animals, compared to controls. The pHe reported by the 3-
APP resonance in NaHCO3-treated tumours is high, 7.84 ± 0.13
pH unit. The pHi values in the same animals were 7.39 ± 0.12. The
imprecision in both the pHe and pHi measurements are likely
higher due to these values being near the alkaline extreme of the
titration curves for both 3-APP and Pi respectively. Nevertheless,
the data clearly show that chronic bicarbonate therapy effectively
alkalinizes the pHe in vivo, generating an (in–out) DpH of approx-
imately – 0.45 pH unit, compared to a DpH of + 0.20 in untreated
animals.
Bicarbonate chemosensitizes tumour xenografts
in vivo
According to the measured pH gradients, the theoretical
cytosolic–extracellular drug ratio should be 1.6 in bicarbonate-
treated animals, and 0.6 in controls, leading to a 2.5-fold increase
in doxorubicin sensitivity (Table 1). To test this, MCF-7 tumours
were grown in the mammary fat pads of 6-week-old female SCID
mice, to sizes of 50–200 mm3, and were forcibly randomized
according to tumour size into four groups.
Groups A and C were given normal water ad libitum, while the
water given to groups B and D was supplemented with 200 mM
NaHCO3. The start of the bicarbonate treatment was designated as
day 1. On days 3, 7 and 11, animals in groups C and D were
injected i.p. with doxorubicin while animals in groups A and B
(n = 10 each) received saline injections of the same volume, as per
established protocols (Paine-Murrieta et al, 1997). The maximum
tolerated dose (MTD) of SCID mice for doxorubicin under this
regimen is a cumulative 6.7 mg kg–1 (Paine-Murrieta et al, 1997).
Initial experiments used three doses of doxorubicin at 2.0 mg kg–1
(cohorts C1/D1) and this was reduced in later experiments to three
doses at 1.6 mg kg–1 (cohorts C2/D2) to reduce morbidity. In all
1008 N Raghunand et al
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Figure 2 Measurement of tumour pH with 31P MRS. (A) In vivo 31P NMR
spectrum of MCF-7 tumour grown in mammary fat pad of severe combined
immunodeficient (SCID) mouse. The in vivo 31P spectra were processed by
Fourier transformation with 15 Hz exponential line broadening and
referenced to the a-resonance of NTP at –10.05 ppm. The intra and
extracellular pH values were obtained from the chemical shifts of Pi and 3-
APP respectively (McCoy et al, 1995; Raghunand et al, 1999a). Pi, inorganic
phosphate; NTP, nucleoside triphosphates; PME, phosphomonoesters.
(B) Downfield region of spectra from control and NaHCO3-treated mice.
Downfield region of 31P MR spectra showing 3-APP resonance from MCF-7
tumours in SCID mice. The dotted line (downfield resonance) is from control
mouse at pHe 6.57 and the solid line (upfield resonance) is from mouse
given 200 mM NaHCO3 ad libitum for 4 days, showing a pHe of 7.72.
Acquisition conditions were identical to those in Figure 1Aexperiments, the incidence of morbidity following drug treatment
was identical between groups C and D. In parallel experiments,
three doses of i.p. doxorubicin at 2.0 mg kg–1 on days 1, 5 and 9
gave no evidence of vesication upon day 10 necropsy. Tumour
volumes and animal weights were monitored every 2–3 days. For
graphing purposes, tumour volumes for each mouse were normal-
ized to day 1. As shown in Figure 3B, doxorubicin has a signifi-
cant effect on the tumour growth rate, and this effect is greater in
animals co-treated with bicarbonate. For statistical analyses,
normalized data were used to calculate specific tumour growth
rates for each tumour, from day 9 onward. The means of these
normalized tumour growth rates are shown in Figure 3C.
Regardless of dose, the tumour growth rate was significantly (P ≤
0.03) slower in the bicarbonate plus doxorubicin groups (D1, D2),
compared to the doxorubicin alone groups (C1, C2) (Table 2).
Furthermore, bicarbonate alone had no significant effect on the
growth rate (P > 0.4, A vs B). Table 2 also shows that the tumour
growth delays (T–C) were 15 and 22 days at 300 mm3 for groups C
and D respectively. However, since the slopes of the growth curves
diverge, the T–C increased with time, and thus cannot be used to
pH and chemotherapy 1009
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Figure 3 In vivo effects of combination chemotherapy. (A) pHi and pHe of MCF-7 tumours in control (triangles) and bicarbonate-treated (circles) mice. pHi and
pHe values were measured using 31P MRS, as described for Figure 1. These pHe data were collected 4–10 days following commencement of bicarbonate
therapy. Closed symbols represent the intracellular pH values, measured with Pi, and the open symbols represent extracellular pH values, measured with 3-
APP. Arrows indicate the direction of the intra- to extracellular gradient, and dotted lines represent independent linear regressions of the four data sets. (B)
Tumour volumes as a function of time. MCF-7 tumours were grown in SCID mice to volumes of 50–200 mm3, after which time they were randomized into four
cohorts (A–D). Beginning on day 1, cohorts A and C received drinking water, whereas cohorts B and D received 200 mM NaHCO3. On days 1, 5 and 9, animals
of cohorts C and D were injected i.p. with doxorubicin (arrows), whereas animals from cohorts A and B were injected with saline. On day 15, animals of cohorts
B and D were placed back on drinking water. For the purpose of display, tumour volumes were normalized to 100% on day 4. Data points represent the pooled
means of 3–16 measurements at each time point from all experiments. (C) Specific growth rates. The rate of increase in tumour size was determined between
days 9 and 15 for each animal by linear regression and expressed as fraction of surviving mice per day individual tumour. The illustrated data represent the
mean ± standard deviation of these data sets binned by cohort. The cohorts were as described in Figure 3B, except that cohorts C1/D1 and C2/D2 were
separated since they received doxorubicin at 2.0 and 1.6 mg kg–1 respectively. *Indicates values were significantly different (P < 0.03) by Student’s t-test. (D)
Individual tumour growth curves. Percent of total tumours in a cohort greater than 1000 mm3 are plotted as a function of time since beginning of experiments.
Cohorts are as described for Figure 3B
A
D
C
Breliably calculate log cell kill. The T/C values calculated at day
20 were 0.47 (751/1571) and 0.29 (458/1571) for groups C
and D respectively. A modified (Kaplan–Meier type) survival
plot showing the fraction of remaining animals with small
(< 1000 mm3) tumours is shown in Figure 3D. These data show that
animals receiving doxorubicin plus bicarbonate take significantly
longer to develop larger tumours compared to the other groups.
DISCUSSION
These data indicate that raising pHe increased the cytotoxic effec-
tiveness of doxorubicin both in vitro and in vivo. In-vitro, raising
the pHe from 6.8 to 7.4 resulted in a 2.25-fold enhancement of
cytotoxicity and a 2.56-fold increase in intracellular doxorubicin
concentrations. These data compared well to the 1.97-fold
enhancement predicted from the calculated difference in doxoru-
bicin distributions (Table 1). It is possible that the larger enhance-
ment observed empirically, relative to theory, is due to
sequestration of doxorubicin in acidic vesicles, which was not
accounted for in the theoretical calculations (Altan et al, 1998;
Raghunand et al, 1999b).
In vivo, in the SCID mouse–MCF7 tumour model system used
here, the data clearly show that NaHCO3 effectively raises the pHe
for extended periods of time. Prolonged treatments with bicar-
bonate in drinking water did not have significant effects on animal
well-being.
Nevertheless, for bicarbonate therapy to have clinical utility,
the minimum required treatment time needs to be determined.
Previous protocols involving bicarbonate treatment of humans
have primarily been developed to counteract acidosis caused by
exercise or renal failure (Passfall et al, 1997; Verbitsky et al,
1997). A problem in these protocols is poor patient compliance,
with chronic bicarbonate ingestion. Clinical metabolic alkaliniza-
tion with bicarbonate will be most successful if it is administered
acutely, viz. shortly prior to the time of chemotherapy. Hence,
experiments are underway to determine the time course of alkalin-
ization and whether acute, intermittent alkalinization is as effec-
tive, compared to chronic bicarbonate administration.
Combination therapy with bicarbonate and doxorubicin resulted
in a significantly lowered tumour growth rate compared to treat-
ment with doxorubicin alone. In SCID mice, as in human patients,
doxorubicin alone is not a highly effective cytotoxic agent with
much heterogeneity of response. Many workers have used SCID
mice to test doxorubicin chemotherapy (Liu et al, 1996; Cesano et
al, 1997; Durand and LePard, 1997). However, a recent report
indicates that doxorubicin is not effective to treat tumours in SCID
mice, due to granulocyte toxicity to the host (Polin et al, 1997).
This may be observed in our studies, since the tumour outgrowth
did not occur with the same doubling time as the untreated
tumours. Consequently, log kill values could not be reliably calcu-
lated. However, the T/C value measured at day 20 was 0.29 for
group D, compared to 0.47 for group C. T/C < 44% is considered
significant by the Division of Cancer Treatment (NCI). Thus, this
measure indicates a meaningful boost in therapeutic effectiveness
caused by raising the pH with bicarbonate. In other systems, such
as sygeneic mice (16/C mammary adenocarcinoma in C3H mice),
log kill from doxorubicin can be 2.5–3.0 (T Corbett, personal
communication). Hence, experiments are planned using this more
responsive mouse system, even though it is not a high connectivity
model for human clinical response.
The growth rates resulting from the two different doxorubicin
doses were not significantly different (i.e. C1 vs C2, D1 vs D2).
However, the lower doxorubicin dose did reduce the mortality of
the treated animals during the course of the experiments. At
2 mg kg–1, half of the animals survived in both groups to day 30.
At 1.6 mg kg–1, only one animal from each group (out of eight) did
not survive until day 30. It must be noted that doxorubicin-treated
animals appeared more distressed than controls. By day 15,
animals in groups C and D displayed poor grooming and urinary
discharges. By day 30, all animals in group D were experiencing
anal discharge as well. This suggests that, in addition to the
tumours, bicarbonate also sensitized the intestinal epithelium to
doxorubicin cytotoxicity. Since bicarbonate should only have this
effect on tissues with low initial pHe, this might indicate that
intestinal epithelial cells or colonic crypts have a naturally low
pHe. This side-effect of combination bicarbonate–doxorubicin
chemotherapy might be avoided with shorter bicarbonate treat-
ment times, more selective alkalinizing agents, or protection of the
intestinal epithelium with acid buffers or V-ATPase inhibitors.
Despite the qualitatively poorer condition of group D animals,
there was no significant difference in their body weights,
compared to animals of group C.
Our calculations predict that alkalinization should provide a
two- to threefold increase in the therapeutic efficacy of doxoru-
bicin. This is significant, because many current clinical studies
indicate that threefold accelerated dosing of doxorubicin is more
effective in treating node-positive breast cancers (Bearman et al,
1997). However, doxorubicin has associated cardiotoxicity and
there is a significant morbidity associated with accelerated dosing
regimens. Thus, if two- to threefold increases in cytosolic doxoru-
bicin could be achieved through manipulation of pH, it is likely
that the therapeutic benefits could be realized without the
increased morbidity associated with accelerated dosing.
In summary, the current data indicate that the pHe of human
breast tumour xenografts is acidic and that this reduces the cyto-
toxicity of doxorubicin in vitro and in vivo. Tumour pHe can be
chronically raised by treatment with sodium bicarbonate in the
drinking water of tumour-bearing SCID mice, and this signifi-
cantly increases the chemotherapeutic efficacy of doxorubicin
chemotherapy in vivo.
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